These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36442831)

  • 41. Cost effectiveness of palivizumab in Spain: an analysis using observational data.
    Nuijten MJ; Wittenberg W
    Eur J Health Econ; 2010 Feb; 11(1):105-15. PubMed ID: 19967425
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study.
    Shoukat A; Abdollahi E; Galvani AP; Halperin SA; Langley JM; Moghadas SM
    Lancet Reg Health Am; 2023 Dec; 28():100629. PubMed ID: 38026446
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants.
    Banerji A; Lanctôt KL; Paes BA; Masoud ST; Tam DY; Macdonald WA; Roberts A
    Pediatr Infect Dis J; 2009 Aug; 28(8):702-6. PubMed ID: 19461555
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children.
    Nair H; Verma VR; Theodoratou E; Zgaga L; Huda T; Simões EA; Wright PF; Rudan I; Campbell H
    BMC Public Health; 2011 Apr; 11 Suppl 3(Suppl 3):S30. PubMed ID: 21501449
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Optimal Respiratory Syncytial Virus intervention programmes using Nirsevimab in England and Wales.
    Hodgson D; Koltai M; Krauer F; Flasche S; Jit M; Atkins KE
    Vaccine; 2022 Nov; 40(49):7151-7157. PubMed ID: 36328884
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Passive immunisation against respiratory syncytial virus: a cost-effectiveness analysis.
    Rietveld E; Steyerberg EW; Polder JJ; Veeze HJ; Vergouwe Y; Huysman MW; de Groot R; Moll HA
    Arch Dis Child; 2010 Jul; 95(7):493-8. PubMed ID: 20504841
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Economic Burden and Health-Related Quality of Life of Respiratory Syncytial Virus and Influenza Infection in European Community-Dwelling Older Adults.
    Mao Z; Li X; Korsten K; Bont L; Butler C; Wildenbeest J; Coenen S; Hens N; Bilcke J; Beutels P;
    J Infect Dis; 2022 Aug; 226(Suppl 1):S87-S94. PubMed ID: 35961055
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mathematical modelling of respiratory syncytial virus (RSV) in low- and middle-income countries: A systematic review.
    Mezei A; Cohen J; Renwick MJ; Atwell J; Portnoy A
    Epidemics; 2021 Jun; 35():100444. PubMed ID: 33662812
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A cost-benefit analysis of the immunisation of children against respiratory syncytial virus (RSV) using the English Hospital Episode Statistics (HES) data set.
    Thomas G
    Eur J Health Econ; 2018 Mar; 19(2):177-187. PubMed ID: 25557555
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The burden of RSV-associated illness in children aged < 5 years, South Africa, 2011 to 2016.
    Moyes J; Tempia S; Walaza S; McMorrow ML; Treurnicht F; Wolter N; von Gottberg A; Kahn K; Cohen AL; Dawood H; Variava E; Cohen C
    BMC Med; 2023 Apr; 21(1):139. PubMed ID: 37038125
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluating the next generation of RSV intervention strategies: a mathematical modelling study and cost-effectiveness analysis.
    Hodgson D; Pebody R; Panovska-Griffiths J; Baguelin M; Atkins KE
    BMC Med; 2020 Nov; 18(1):348. PubMed ID: 33203423
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.
    Li Y; Wang X; Blau DM; Caballero MT; Feikin DR; Gill CJ; Madhi SA; Omer SB; Simões EAF; Campbell H; Pariente AB; Bardach D; Bassat Q; Casalegno JS; Chakhunashvili G; Crawford N; Danilenko D; Do LAH; Echavarria M; Gentile A; Gordon A; Heikkinen T; Huang QS; Jullien S; Krishnan A; Lopez EL; Markić J; Mira-Iglesias A; Moore HC; Moyes J; Mwananyanda L; Nokes DJ; Noordeen F; Obodai E; Palani N; Romero C; Salimi V; Satav A; Seo E; Shchomak Z; Singleton R; Stolyarov K; Stoszek SK; von Gottberg A; Wurzel D; Yoshida LM; Yung CF; Zar HJ; ; Nair H;
    Lancet; 2022 May; 399(10340):2047-2064. PubMed ID: 35598608
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prophylaxis against respiratory syncytial virus (RSV), varicella, and pneumococcal infections: Economic-based decision-making.
    Strutton DR; Stang PE
    J Pediatr; 2003 Nov; 143(5 Suppl):S157-62. PubMed ID: 14615715
    [TBL] [Abstract][Full Text] [Related]  

  • 54. RSV disease in infants and young children: Can we see a brighter future?
    Baraldi E; Checcucci Lisi G; Costantino C; Heinrichs JH; Manzoni P; Riccò M; Roberts M; Vassilouthis N
    Hum Vaccin Immunother; 2022 Nov; 18(4):2079322. PubMed ID: 35724340
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32-35 weeks in Spain].
    Lázaro y de Mercado P; Figueras Aloy J; Doménech Martínez E; Echániz Urcelay I; Closa Monasterolo R; Wood Wood MA; Fitch Warner K
    An Pediatr (Barc); 2006 Oct; 65(4):316-24. PubMed ID: 17020726
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings.
    Marchetti A; Lau H; Magar R; Wang L; Devercelli G
    Clin Ther; 1999 Apr; 21(4):752-66. PubMed ID: 10363740
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods and Input Data.
    Treskova M; Pozo-Martin F; Scholz S; Schönfeld V; Wichmann O; Harder T
    Pharmacoeconomics; 2021 Mar; 39(3):287-315. PubMed ID: 33462760
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden.
    Neovius K; Buesch K; Sandström K; Neovius M
    Acta Paediatr; 2011 Oct; 100(10):1306-14. PubMed ID: 21477089
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Respiratory syncytial virus immune globulin: decisions and costs.
    Barton LL; Grant KL; Lemen RJ
    Pediatr Pulmonol; 2001 Jul; 32(1):20-8. PubMed ID: 11416872
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The cost-effectiveness of a hypothetical respiratory syncytial virus vaccine in the elderly.
    Gessner BD
    Vaccine; 2000 Feb; 18(15):1485-94. PubMed ID: 10618546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.